Laura Glickman

Laura Glickman

Company: Actym Therapeutics

Job title: Vice President, Research & Co- Founder

Seminars:

Speaker Q&A 12:50 pm

Read more

day: Day One

STACT: A Novel Therapeutic Platform that Delivers Combination STING Immunotherapy to Tumor Resident Myeloid Cells After IV Dosing 12:25 pm

In a metastatic disease setting, systemically-administered immunotherapies will be required to promote proper T-cell infiltration in immune-excluded tumors Many agents are in development to properly inflame these tumors, including STING agonists, co-stimulatory receptor agonists and type I/II cytokines, but are too toxic or ineffective when systemically administered Here we describe a microbial-based immunotherapy platform, STACT…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.